USPTO Examiner VAN DRUFF SYDNEY - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18611087HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFORMarch 2024May 2025Allow1410YesNo
18595279LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEMarch 2024April 2025Abandon1310NoNo
18595275LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEMarch 2024December 2024Abandon910NoNo
18383043ANTI-CEACAM6 ANTIBODIES AND METHODS OF USEOctober 2023October 2024Allow1110NoNo
18481547METHODS OF USING RARy AGONISTS FOR CANCER TREATMENTOctober 2023June 2024Allow800YesNo
18227828LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAMEJuly 2023April 2025Abandon2110NoNo
18216085Anti-Axl Antagonistic AntibodiesJune 2023October 2024Abandon1610NoNo
18255880B7-H3 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOFJune 2023December 2024Abandon1820NoNo
18256045TROP2 TARGETING ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREFORJune 2023December 2024Abandon1820NoNo
18191372Method And MoleculesMarch 2023March 2025Abandon2421NoNo
18173413LINKERS FOR ANTIBODY DRUG CONJUGATESFebruary 2023May 2024Allow1410NoNo
18172123ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESFebruary 2023June 2024Abandon1610NoNo
18164519ANTI-CCR7 ANTIBODY DRUG CONJUGATESFebruary 2023July 2024Allow1810NoNo
18161423PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERSJanuary 2023March 2024Allow1310NoNo
18145811PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USESDecember 2022May 2024Abandon1610NoNo
18062355ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOFDecember 2022July 2024Allow2010NoNo
17993528METHODS OF USING RARy AGONISTS FOR CANCER TREATMENTNovember 2022June 2023Allow1810YesNo
17986430COMBINATION TAXOID NANOEMULSION WITH IMMUNOTHERAPY IN CANCERNovember 2022September 2024Allow2220YesNo
17823117IMMUNOGENIC COMPOUNDS FOR CANCER THERAPYAugust 2022October 2024Allow2711YesNo
17820179COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORSAugust 2022February 2024Allow1820YesNo
17817100HUMANIZED ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE (OACGD2)August 2022September 2024Abandon2630YesNo
17851618NaPi2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFJune 2022November 2023Abandon1610NoNo
17838016BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATESJune 2022September 2023Allow1610NoNo
17744134METHODS AND MATERIALS FOR TREATING CYTOKINE RELEASE SYNDROMEMay 2022October 2023Abandon1710NoNo
17560232ANTI-CEACAM6 ANTIBODIES AND METHODS OF USEDecember 2021July 2023Allow1910NoNo
17516916Anti-Axl Antagonistic AntibodiesNovember 2021March 2023Allow1710NoNo
17598280Antibodies to Pyroglutamate Amyloid-B and Uses ThereofSeptember 2021February 2025Allow4010NoNo
17425006COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMORJuly 2021May 2025Allow4610NoNo
17424889NOVEL ANTI-CD40 ANTIBODIESJuly 2021August 2024Allow3610NoNo
17423775VARIANTS OF ERYTHROFERRONE AND THEIR USEJuly 2021October 2024Abandon4010NoNo
17366837PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERSJuly 2021January 2023Allow1910NoNo
17358703PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERSJune 2021August 2021Allow200YesNo
17348236COMPOUNDS AND CONJUGATES THEREOFJune 2021July 2022Allow1321YesNo
17413152ANTI-IL-17A ANTIBODY AND USE THEREOFJune 2021September 2024Allow4010NoNo
17339549ANTI-BCMA ANTIBODY-DRUG CONJUGATES AND METHODS OF USEJune 2021March 2024Allow3311NoNo
17281062ANTI-B7H3 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICINAL USE THEREOFMarch 2021March 2025Allow4720NoNo
17276706DRUG CONJUGATE COMPRISING QUINOLINE DERIVATIVESMarch 2021March 2024Allow3600NoNo
17276686ANTI-TNFR2 ANTIBODIES AND USES THEREOFMarch 2021July 2024Abandon4010NoNo
17275030EPITOPESMarch 2021May 2025Allow5011YesNo
17193631COMBINATION THERAPY COMPRISING AXL/MER AND PD-1/PD-L1 INHIBITORSMarch 2021September 2024Allow4330NoNo
17189918Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and CancersMarch 2021November 2023Abandon3210NoNo
17272241Anti-CD3 Antibody Folate Bioconjugates and Their UsesFebruary 2021April 2025Allow5020YesNo
17185012CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOFFebruary 2021December 2023Allow3411NoNo
17264721Linkers and conjugatesJanuary 2021April 2025Allow5020YesNo
17263322PROTEIN RECOGNIZING DRUG MOIETY OF ANTIBODY-DRUG CONJUGATEJanuary 2021March 2025Allow4911NoNo
17262917OFF-THE-SHELF CANCER VACCINESJanuary 2021April 2025Allow5011NoNo
17156401COMPOSITIONS, METHODS AND USES FOR MODULATING THE TUMOR MICROENVIRONMENT TO ENHANCE ANTITUMOR IMMUNITYJanuary 2021January 2025Abandon4811NoNo
17154350HUMAN ANTI-IFN-ALPHA ANTIBODIESJanuary 2021November 2023Allow3400NoNo
17258348BISPECIFIC ANTIBODIES TARGETING IMMUNE CHECKPOINTSJanuary 2021December 2023Allow3510NoNo
17059019ANTIBODY BINDING TO AXL PROTEIN AND APPLICATION THEREOFNovember 2020February 2024Allow3910YesNo
17058472PYRROLOBENZODIAZEPINE CONJUGATESNovember 2020April 2024Abandon4110NoNo
17055499AXL-TARGETING ANTIBODY, ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOFNovember 2020November 2023Allow3610NoNo
17042872SELECTIVE REDUCTION OF ANTIBODIESSeptember 2020March 2024Abandon4110NoNo
17040269HUMAN PD-L2 ANTIBODIES AND METHODS OF USE THEREFORSeptember 2020December 2023Allow3910NoNo
16978991RELEASABLE ANTIBODY CONJUGATESSeptember 2020August 2024Abandon4701NoNo
17011542METHOD OF PRODUCING IMMUNOTHERAPY VACCINESeptember 2020February 2023Allow3010NoNo
16996949THERAPEUTIC ANTIBODY AND USES THEREOFAugust 2020August 2022Abandon2310NoNo
16971219ANTIBODY-DRUG CONJUGATE HAVING ACIDIC SELF-STABILIZATION JUNCTIONAugust 2020June 2025Allow5821YesNo
16993539Formulations of Benzazepine Conjugates and Uses ThereofAugust 2020April 2023Abandon3210NoNo
16966072METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORSJuly 2020September 2023Abandon3811NoNo
16963380ARGINASE SUPPRESSION FOR CANCER TREATMENTJuly 2020October 2024Abandon5031NoNo
16933349MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDSJuly 2020February 2024Abandon4310NoNo
16768036COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD2+ CELLSMay 2020October 2023Abandon4101NoNo
16765486MULTISPECIFIC ANTIGEN BINDING PROTEINSMay 2020February 2024Abandon4411NoNo
16763705METHODS AND COMPOSITIONS FOR TARGETING DEVELOPMENTAL AND ONCOGENIC PROGRAMS IN H3K27M GLIOMASMay 2020May 2024Allow4941YesNo
16763185HUMANIZED ANTIBODIES TARGETING HUMAN TISSUE FACTORMay 2020March 2022Allow2210YesNo
16760910USE OF NOX INHIBITORS FOR TREATMENT OF CANCERMay 2020March 2024Allow4731YesNo
16862358THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATESApril 2020April 2023Allow3520YesNo
16860822BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATESApril 2020May 2022Allow2410YesNo
16856689CONJUGATES AND METHODS OF USE THEREOF FOR SELECTIVE DELIVERY OF IMMUNE-MODULATORY AGENTSApril 2020February 2023Abandon3410NoNo
16852371METHODS OF TREATING RENAL CANCER WITH AN ANTI- PSMA/CD3 ANTIBODYApril 2020May 2022Abandon2510NoNo
16650429COMPOUNDS, REAGENTS, AND USES THEREOFMarch 2020January 2023Allow3410NoNo
16647711IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCERMarch 2020December 2024Allow5731NoNo
16645315ANTITUMOR AGENT AND ANTITUMOR EFFECT POTENTIATORMarch 2020July 2024Allow5350YesYes
16644751HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPYMarch 2020June 2022Abandon2701NoNo
16643756PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCERMarch 2020August 2022Abandon2910NoNo
16794069COMPOUNDS FOR TARGETED IMMUNOTHERAPYFebruary 2020September 2023Abandon4330YesYes
16794056COMPOUNDS FOR TARGETED IMMUNOTHERAPYFebruary 2020February 2024Abandon4850YesNo
16639667PYRROLOBENZODIAZEPINE CONJUGATESFebruary 2020December 2022Allow3410NoNo
16780711ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESFebruary 2020November 2022Allow3311YesNo
16626456ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOFDecember 2019September 2022Allow3211NoNo
16711652COMPOUNDS AND COMPOSITIONS FOR TREATING EGFR EXPRESSING TUMORSDecember 2019February 2023Allow3921YesNo
16619846Engineered Antibody Compounds and Conjugates ThereofDecember 2019April 2025Abandon6041NoNo
16616148LINKERS FOR ANTIBODY DRUG CONJUGATESNovember 2019November 2022Allow3611NoNo
16691437ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USENovember 2019December 2023Abandon4921YesNo
16615582METHOD AND MOLECULESNovember 2019October 2022Allow3520YesNo
16604700Immunoconjugate Synthesis MethodOctober 2019January 2023Abandon3920NoNo
16496286TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENTSeptember 2019October 2022Allow3720YesNo
16570834PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPYSeptember 2019January 2023Abandon4030NoNo
16490892USE OF MTOR INHIBITOR AND CHLOROQUINE FOR TREATING CANCERSeptember 2019December 2021Allow2710YesNo
16553339COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORSAugust 2019May 2022Allow3311NoNo
16488459IMMUNOCYTOKINE COMBINATION THERAPYAugust 2019June 2023Abandon4520NoNo
16548215METHODS AND MATERIALS FOR TREATING CYTOKINE RELEASE SYNDROMEAugust 2019February 2022Allow3020NoNo
16542642NaPi2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFAugust 2019March 2022Allow3110YesNo
16485100ANTIBODIES TO TIP1 AND METHODS OF USE THEREOFAugust 2019February 2022Allow3010YesNo
165294572H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFORAugust 2019March 2022Allow3111YesNo
16482173ANTI-CCR7 ANTIBODY DRUG CONJUGATESJuly 2019October 2022Allow3911YesNo
16480557COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDSJuly 2019November 2021Allow2811NoNo
16513194METHODS OF SENSITIZING CANCER CELLS TO IMMUNE CELL KILLINGJuly 2019January 2024Abandon5460YesNo
16471395ANTI-LILRB3 ANTIBODIES AND METHODS OF USE THEREOFJune 2019June 2023Allow4811NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VAN DRUFF, SYDNEY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.6%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
5
(100.0%)
Filing Benefit Percentile
0.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner VAN DRUFF, SYDNEY - Prosecution Strategy Guide

Executive Summary

Examiner VAN DRUFF, SYDNEY works in Art Unit 1643 and has examined 119 patent applications in our dataset. With an allowance rate of 63.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner VAN DRUFF, SYDNEY's allowance rate of 63.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by VAN DRUFF, SYDNEY receive 1.60 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by VAN DRUFF, SYDNEY is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +31.1% benefit to allowance rate for applications examined by VAN DRUFF, SYDNEY. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.7% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 27.3% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 92.9% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.